Paper41006969
Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know.
Jimenez DG and 3 others. Children (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know. Papers, record 41006969. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41006969
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31400996 | Reference values for the phase angle of the electrical bioimpedance: Systematic review and meta-analysis involving more than 250,000 subjects. | Clin Nutr | 2020 | https://conductscience.org/library/papers/31400996 | PubMed |
| 2 | 37780857 | The gut-lung axis in the CFTR modulator era. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37780857 | PubMed |
| 3 | 35059303 | Treatment of cystic fibrosis related bone disease. | J Clin Transl Endocrinol | 2022 | https://conductscience.org/library/papers/35059303 | PubMed |
| 4 | 36979360 | Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation. | Biomolecules | 2023 | https://conductscience.org/library/papers/36979360 | PubMed |
| 5 | 39800644 | Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis. | J Cyst Fibros | 2025 | https://conductscience.org/library/papers/39800644 | PubMed |
| 6 | 39019666 | Characterization of bone disease in cystic fibrosis. | Med Clin (Barc) | 2025 | https://conductscience.org/library/papers/39019666 | PubMed |
| 7 | 32532673 | Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review. | J Acad Nutr Diet | 2021 | https://conductscience.org/library/papers/32532673 | PubMed |
| 8 | 37495468 | The natural history of cystic fibrosis liver disease a prospective cohort study. | J Cyst Fibros | 2023 | https://conductscience.org/library/papers/37495468 | PubMed |
| 9 | 39671064 | Integration of Non-invasive Screening for Cystic Fibrosis Related Liver Disease in the Regular Follow-Up for Cystic Fibrosis. | Dig Dis Sci | 2025 | https://conductscience.org/library/papers/39671064 | PubMed |
| 10 | 25238538 | Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. | J Gastroenterol Hepatol | 2014 | https://conductscience.org/library/papers/25238538 | PubMed |
| 11 | 30546102 | Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. | Sci Rep | 2018 | https://conductscience.org/library/papers/30546102 | PubMed |
| 12 | 36921081 | Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele. | Am J Respir Crit Care Med | 2023 | https://conductscience.org/library/papers/36921081 | PubMed |
| 13 | 19949942 | The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. | Calcif Tissue Int | 2010 | https://conductscience.org/library/papers/19949942 | PubMed |
| 14 | 37230807 | Nutritional considerations for a new era: A CF foundation position paper. | J Cyst Fibros | 2023 | https://conductscience.org/library/papers/37230807 | PubMed |
| 15 | 40379512 | Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients. | An Pediatr (Engl Ed) | 2025 | https://conductscience.org/library/papers/40379512 | PubMed |
| 16 | 39760529 | Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI). | Pediatr Pulmonol | 2025 | https://conductscience.org/library/papers/39760529 | PubMed |
| 17 | 28986022 | Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. | J Cyst Fibros | 2017 | https://conductscience.org/library/papers/28986022 | PubMed |
| 18 | 37678151 | Cystic fibrosis liver disease in the post-modulator era. | Curr Opin Pulm Med | 2023 | https://conductscience.org/library/papers/37678151 | PubMed |
| 19 | 26431978 | Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. | Osteoporos Int | 2016 | https://conductscience.org/library/papers/26431978 | PubMed |
| 20 | 38116856 | Body composition in children with cystic fibrosis treated with CFTR modulators versus modulator naïve individuals. | Pediatr Pulmonol | 2024 | https://conductscience.org/library/papers/38116856 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41006969
GET https://conductscience.org/api/papers/v1/41006969/references?page=2